NCT00359619 - Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine | Biotech Hunter

Enrollment

383

Participants

Timeline

Start Date

September 12, 2006

Primary Completion Date

January 30, 2007

Study Completion Date

January 30, 2007

Conditions

Infections, PapillomavirusPapillomavirus Vaccines

Interventions

BIOLOGICAL

CervarixTM

Subjects were administered three doses of HPV vaccine

BIOLOGICAL

HPV investigational vaccine GSK568893A, different formulations

Subjects were administered three doses of HPV investigational vaccine

Trial Locations (10)

GSK Investigational Site, Brussels

GSK Investigational Site, Wilrijk

GSK Investigational Site, Leuven

GSK Investigational Site, Tienen

GSK Investigational Site, Liège

GSK Investigational Site, Ghent

GSK Investigational Site, Denver

GSK Investigational Site, Golden

GSK Investigational Site, Salt Lake City

GSK Investigational Site, Salt Lake City